Helping you detect, treat and manage arthritis

JointHealth™ insight: The latest news on provincial drug formulary

In this issue of JointHealth™ insight, Arthritis Consumer Experts (ACE) maps out the latest news for you about provincial drug formulary listing decisions. It contains information about important changes to provincial drug formularies and what it means for Canadians living with inflammatory arthritis. The changes covered in this update affect people living with rheumatoid arthritis (RA), ankylosing spondylitis (AS), psoriatic arthritis (PsA) and juvenile idiopathic arthritis (JIA).

Map of Canada with highlights of changesManitoba
The following medication has been listed for reimbursement on the provincial drug formulary:

  • Tofacitinib citrate (Xeljanz®) for the treatment of RA

New Brunswick
The following medications have been listed for reimbursement on the provincial drug formulary:

  • Certolizumab pegol (Cimzia®) for the treatment of RA, AS and PsA
  • Infliximab (Infectra®) for the treatment of RA, AS and PsA
  • A listing criteria change has occurred for infliximab (Remicade®) for the treatment of RA, AS and PsA

Please note that all Special Authorization (SA) requests for reimbursement of infliximab for patients who have never been on infliximab for their RA, AS and PsA will be approved for the Infectra® brand of infliximab only. Patients who received SA approval for the Remicade® brand of infliximab before June 1, 2016 will continue to have this brand covered. They will also be eligible for reimbursement of the Infectra® brand.

Nova Scotia
The following medication has been listed for reimbursement on the provincial drug formulary:

  • Infliximab (Infectra®) for the treatment of RA and AS
  • A listing criteria change has occurred for infliximab (Remicade®) for the treatment of RA and AS.
  • The listing criteria for rheumatoid arthritis has been updated for all medications listed in the Report Card.
  • The listing criteria for adalimumab (Humira®) for juvenile idiopathic arthritis has been expanded to include polyarticular juvenile idiopathic arthritis.

Please note that for infliximab-naïve patients whose infliximab therapy is initiated after June 1, 2016, Infectra® will be the product approved for RA and AS.

Prince Edward Island
The following medications have been listed for reimbursement on the provincial drug formulary:

  • Certolizumab pegol (Cimzia®) for the treatment of AS and PsA
  • Infliximab (Infectra®) for the treatment of RA, AS and PsA
  • A listing criteria change has occurred for infliximab (Remicade®) for the treatment of RA, AS and PsA.
  • The listing criteria for rheumatoid arthritis has been updated for all medications listed in the JointHealth™ Arthritis Medications Report Card.

Please note that for infliximab-naïve patients (those who have never been on infliximab) effective June 27, 2016 or later, Infectra® will be the product approved for RA, AS and PsA.

Ontario
The following medication has been declined for listing in the provincial drug formulary:

  • Apremilast (Otezla®) for the treatment of PsA

Click here to view the full version of the JointHealth™ Arthritis Medications Report Card.

About the medications in this Report Card update and their listing decisions

News about arthritis Medications